Vimta Labs Ltd
Incorporated in 1990, Vimta Labs Ltd is a contract research and testing services provider[1]
- Market Cap ₹ 1,696 Cr.
- Current Price ₹ 764
- High / Low ₹ 805 / 390
- Stock P/E 31.8
- Book Value ₹ 155
- Dividend Yield 0.26 %
- ROCE 17.6 %
- ROE 13.5 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Part of BSE Allcap BSE SmallCap BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|
181 | 211 | 278 | 318 | 318 | 321 | |
151 | 158 | 198 | 223 | 231 | 219 | |
Operating Profit | 30 | 53 | 80 | 95 | 87 | 102 |
OPM % | 17% | 25% | 29% | 30% | 27% | 32% |
3 | 1 | 0 | 3 | 4 | -1 | |
Interest | 4 | 2 | 2 | 3 | 2 | 2 |
Depreciation | 21 | 23 | 23 | 31 | 34 | 33 |
Profit before tax | 8 | 29 | 56 | 65 | 54 | 66 |
Tax % | 17% | 25% | 26% | 26% | 25% | |
7 | 21 | 41 | 48 | 41 | 50 | |
EPS in Rs | 3.10 | 9.68 | 18.69 | 21.77 | 18.50 | 22.56 |
Dividend Payout % | 0% | 21% | 11% | 9% | 11% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 15% |
TTM: | 4% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 24% |
TTM: | 24% |
Stock Price CAGR | |
---|---|
10 Years: | 26% |
5 Years: | 51% |
3 Years: | 26% |
1 Year: | 80% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 17% |
Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 |
Reserves | 168 | 190 | 230 | 277 | 315 | 338 |
33 | 30 | 19 | 15 | 19 | 12 | |
40 | 50 | 54 | 65 | 61 | 86 | |
Total Liabilities | 246 | 274 | 307 | 362 | 400 | 440 |
138 | 135 | 169 | 175 | 171 | 183 | |
CWIP | 2 | 17 | 0 | 12 | 59 | 75 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 |
106 | 122 | 138 | 175 | 170 | 183 | |
Total Assets | 246 | 274 | 307 | 362 | 400 | 440 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
24 | 37 | 59 | 88 | 61 | |
-21 | -32 | -38 | -57 | -76 | |
-1 | -5 | -17 | -11 | -2 | |
Net Cash Flow | 3 | 1 | 5 | 20 | -17 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 117 | 127 | 101 | 92 | 100 |
Inventory Days | 191 | 140 | 115 | 187 | 185 |
Days Payable | 117 | 142 | 82 | 119 | 62 |
Cash Conversion Cycle | 191 | 125 | 134 | 159 | 223 |
Working Capital Days | 100 | 114 | 94 | 82 | 101 |
ROCE % | 14% | 24% | 25% | 18% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
12 Nov - Transcript of the H1/Q2-2024-25 earnings/investor call held on 08th November 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
9 Nov - Audio recording of Q2-FY 2024-25 earnings call available.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Nov - Standalone and Consolidated Unaudited Financial Results for the 2nd Quarter/Half Year ended 30th September 2024, Published in Financial Express (English) and Nava Telangana (Telugu) on …
-
Announcement under Regulation 30 (LODR)-Investor Presentation
8 Nov - Investor presentation for Q2 results FY 2024-25.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
8 Nov - Vimta Labs reports Q2 FY25 financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Oct 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Jun 2020TranscriptPPT
-
Feb 2020TranscriptPPT
-
Nov 2019TranscriptPPT
Business Overview:[1]
VLL is is in the business of contract research and testing in the fields of biologics, small molecules, agro -chemicals, food & beverages, electronics, clinical diagnostics, medical devices, home and personal care products, and environment testing